SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (245)1/20/1999 2:21:00 AM
From: Larry Liebman  Read Replies (1) | Respond to of 626
 
No, I don't think so. The CFO saw the "schizophrenic market" approaching $4 billion. The impression he left was that Novartis was not interested in just a 10% share, but the CFO wanted to remain conservative, so he assumed a 10% share. What I want to know, is "if" Iloperidone is successful, why would Novartis want to pay 10% to TTP? Would it not be more cost efficient to simply take TTP out?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News